Treatment of Advanced and Metastatic NSCLC: Getting From the Good to the Best

Benjamin Levy, MD


September 28, 2022

Benjamin Levy, MD, considers the realignment of treatments for non–small cell lung cancer (NSCLC) in which established therapies in the advanced setting are now being applied in early-stage disease, prompting a new concern for proper regimen sequencing in order to improve patient outcomes.

Dr Levy points to signs of even greater innovations on the horizon, such as CAR T-cell therapy, which together with other immune therapies promise to bring fully realized personalized care for patients with lung cancer into the clinical mainstream.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.